• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, October 1, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Technology

Groundbreaking Nature Study Unveils Innovative Approach to In Vivo Gene Therapy for Blood Stem Cells

Bioengineer by Bioengineer
May 28, 2025
in Technology
Reading Time: 4 mins read
0
high trafficking of blood stem cells in the circulation early post-natally allows lentiviral-vector mediated in vivo gene transfer
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

high trafficking of blood stem cells in the circulation early post-natally allows lentiviral-vector mediated in vivo gene transfer

A team of researchers at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy, has made significant strides in the field of gene therapy, particularly focused on hematopoietic stem cells. Their recent findings suggest that there exists a critical window shortly after birth where these blood stem cells, which circulate in the bloodstream, can be targeted for gene therapy with enhanced effectiveness. This groundbreaking study, published in the prestigious journal Nature, provides a potential alternative treatment approach for genetic blood disorders, potentially eliminating the need for conventional stem cell transplantation or chemotherapy, which can be invasive and fraught with complications.

Historically, gene therapy using lentiviral vectors has demonstrated notable successes when performed ex vivo, where a patient’s stem cells are extracted, modified in a laboratory setting, and then reinfused after undergoing chemotherapy. One prominent example of this application is the therapy for metachromatic leukodystrophy (MLD), developed at SR-Tiget and approved in Europe and the United States. However, while this methodology has proven effective, it is also resource-intensive and presents challenges regarding patient comfort and treatment accessibility.

The innovative approach detailed in the recent study diverges from traditional practices by administering lentiviral vectors directly into the bloodstream in vivo. This method takes advantage of the unique physiological circumstances present in newborn mice. It was observed that during the first two weeks of life, the numbers of hematopoietic stem and progenitor cells (HSPCs) circulating in the bloodstream significantly surpass those found in older animals. This elevated presence of stem cells provides a critical window for gene transfer through systemic injection, facilitating long-term engraftment and the production of multilineage blood cells.

.adsslot_GXINxLDftJ{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_GXINxLDftJ{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_GXINxLDftJ{width:320px !important;height:50px !important;}
}

ADVERTISEMENT

Dr. Michela Milani, the study’s lead author, articulated the significance of these findings by emphasizing the journey of blood stem cells post-birth. According to her, after birth, these stem cells must migrate from the liver—where they reside during the latter stages of pregnancy—to their permanent location in the bone marrow. This journey through the bloodstream creates an unparalleled opportunity for intravenous delivery of gene-modifying vectors, allowing for genetic alterations without the need for prior harvesting or lab processing of the cells.

To substantiate their research further, the team tested their novel in vivo gene transfer approach in mouse models simulating three distinct genetic disorders: adenine deaminase-deficient severe combined immunodeficiency (ADA-SCID), autosomal recessive osteopetrosis, and Fanconi anemia. In all three scenarios, the application of gene transfer was found to yield considerable therapeutic benefits. Notably, in the model pertaining to Fanconi anemia, corrected stem cells were able to progressively repopulate the blood system, thus averting the onset of bone marrow failure. This outcome closely mirrors what has been observed in human gene therapy studies wherein corrected cells demonstrate a survival and growth advantage over defective counterparts.

The researchers also aimed to enhance the effectiveness of gene transfer by utilizing clinically approved mobilizing agents such as G-CSF and Plerixafor. These substances were employed to dislodge stem cells from their tissue niches, ultimately resulting in an increased population of circulating stem cells and extending the potential treatment window to include older mice. Furthermore, the team optimized the lentiviral vectors to bolster their stability and improve cellular uptake—contributing to greater gene transfer efficiencies.

Significantly, the researchers detected HSPCs circulating in the blood of human newborns during the early months of life, which aligns with their earlier observations in mouse models. This finding reinforces the prospect that a similar opportunity for gene therapy may broadly exist in human populations. Dr. Alessio Cantore, another prominent figure in the study, remarked on the implications of their findings, suggesting that they provide proof of principle that in vivo lentiviral gene delivery is feasible during a crucial early-life window. If confirmed in human neonates, this method could have substantial implications for treating genetic diseases like severe immunodeficiencies and Fanconi anemia.

Moreover, the researchers noted an intriguing contrast in the behavior of stem cells between young and adult organisms. When stem cells are harvested from the blood of adult mice or humans, even with the aid of mobilizing drugs, they typically require additional activation signals to facilitate effective lentiviral gene transfer. Conversely, at the newborn stage, not only is there a greater abundance of circulating stem cells, but those cells also exhibit a higher degree of responsiveness to gene transfer efforts. This biological distinction underscores the necessity for further investigations into the mechanisms that govern this increased permissiveness in younger organisms, with aspirations to translate these findings to older age groups.

In conclusion, the research conducted by the SR-Tiget team illuminates a potentially transformative paradigm in the treatment of genetic blood disorders. By harnessing the properties of blood stem cells during a critical developmental window, they have opened a new avenue for therapeutic intervention that could refine and elevate the standard of care for patients burdened by genetic abnormalities. The implications of these findings not only underscore the importance of timing in medical treatments but also mark a pivotal advancement in the burgeoning field of gene therapy.

Subject of Research: Gene therapy targeting hematopoietic stem cells
Article Title: In Vivo Hemopoietic Stem Cell Gene Therapy Enabled by Post-Natal Trafficking
News Publication Date: 28-May-2025
Web References: Nature
References: 10.1038/s41586-025-09070-3
Image Credits: Ella Maru Studio

Keywords

Gene therapy, hematopoietic stem cells, lentiviral vectors, ex vivo, in vivo, genetic disorders, neonatal blood circulation, SR-Tiget, Milan, bone marrow failure, adenine deaminase-deficient severe combined immunodeficiency (ADA-SCID), gene transfer efficiency.

Tags: alternatives to stem cell transplantationbreakthroughs in hematology researchgene therapy accessibility challengesgene therapy for blood disordersgenetic blood disorder treatmentshematopoietic stem cell treatmentin vivo gene therapy techniquesinnovative approaches to gene therapylentiviral vector applicationsnon-invasive gene therapy methodspostnatal gene therapy windowSR-Tiget research advancements

Share12Tweet8Share2ShareShareShare2

Related Posts

New Scientific Findings Reveal How Pianists Manipulate Timbre Through Touch

New Scientific Findings Reveal How Pianists Manipulate Timbre Through Touch

October 1, 2025
College Students’ Travel Choices via Mobile Social Networks

College Students’ Travel Choices via Mobile Social Networks

October 1, 2025

Revitalizing Architectural Heritage Through 3D Reconstruction Technology

October 1, 2025

Advancing Intelligent Expression Evaluation Through Multimodal Interactivity

September 30, 2025

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    89 shares
    Share 36 Tweet 22
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    62 shares
    Share 25 Tweet 16
  • Scientists Discover and Synthesize Active Compound in Magic Mushrooms Again

    57 shares
    Share 23 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Comparative Analysis of Catfish Species in Cage Culture

Research Reveals Connection Between Shift Work and Increased Kidney Stone Risk, Highlighting Lifestyle Influences

New Scientific Findings Reveal How Pianists Manipulate Timbre Through Touch

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 59 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.